Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133019 | 0.94 | CPB2 (0.44) | CPB2MEN1GAAKMT2ANOS1 | |
| SCHEMBL2567893 | 0.93 | CPB2 (0.46) | CPB2MEN1GAAKMT2ANOS1 | |
| SCHEMBL6797401 | 0.88 | NOS1 (0.36) | CPB2MEN1GAAKMT2ANOS1 | |
| SCHEMBL7110422 | 0.88 | NOS1 (0.36) | CPB2MEN1GAAKMT2ANOS1 | |
| SCHEMBL6537553 | 0.87 | CPB2 (0.39) | CPB2MEN1GAAKMT2ANOS1 | |
| SCHEMBL9242626 | 0.86 | GPR84 (0.42) | CPB2MEN1GAAKMT2ANOS1 | |
| SCHEMBL4741502 | 0.82 | TDP1 (0.42) | MEN1GAAKMT2ANOS1NOS3 | |
| SCHEMBL5949606 | 0.82 | CA2 (0.46) | GPR84CTSKFFAR1 | |
| SCHEMBL6535052 | 0.82 | CPB2 (0.39) | CPB2MEN1GAAKMT2ANOS1 | |
| SCHEMBL4741507 | 0.82 | TDP1 (0.42) | MEN1GAAKMT2ANOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1808440-B1 | Non-covalent inhibitors of urokinase and blood vessel formation | WILEX AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7973079-B2 | Methods and compounds for treating retinol-related diseases | REVISION THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2205234-A2 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | Sirion Therapeutics, Inc. (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| WO-2009042444-A2 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | SIRION THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| EP-1808440-A1 | Non-covalent inhibitors of urokinase and blood vessel formation | Wilex AG (DE) | 2007-07-18 | — | — | EP | disclosed |
| EP-1182207-B1 | Non-covalent inhibitors of urokinase and blood vessel formation | DENDREON CORP (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1347784-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | Bristol-Myers Squibb Pharma Company (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6586405-B2 | Therapy for blood disorders | CORVAS INTERNATIONAL, INC. | 2003-07-01 | — | — | US | disclosed |
| WO-2002036173-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-10 | — | — | WO | disclosed |
| US-20020037857-A1 | Non-covalent inhibitors of urokinase and blood vessel formation | CORVAS INTERNATIONAL, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1182207-A2 | Non-covalent inhibitors of urokinase and blood vessel formation | CORVAS INTERNATIONAL, INC. (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2002014349-A2 | NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION | CORVAS INTERNATIONAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088435-A1 | METHODS AND COMPOUNDS FOR TREATING RETINOL-RELATED DISEASES | RBP1, RBP4, ALDH1A2 | CPB2 2264/4885MEN1 4166/4885GAA 308/4885 |
| US-20020037857-A1 | Non-covalent inhibitors of urokinase and blood vessel formation | PLAU, PLAT, PLG | CPB2 23/4885MEN1 3439/4885GAA 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.